Evidence-led panel
Selected canine variants are assessed against the strength, relevance and clinical limitations of the available evidence.
Canine pharmacogenomics · In development
Loom is developing a canine pharmacogenomics panel with veterinary-facing interpretation, designed to help clinicians understand how inherited differences may influence a dog’s response to selected medicines.
Why canine PGx
Genetic differences can influence how some dogs respond to particular medicines, yet the available evidence remains fragmented and difficult to apply in everyday practice.
Loom is translating defensible canine pharmacogenomic evidence into a format designed for veterinary use. The aim is to make relevant genetic information accessible at the point of clinical decision-making, with clear limits where the science is still developing.
What Loom is developing
The platform brings together a multi-gene panel, a veterinary-facing interpretation layer and a growing evidence base designed to strengthen over time.
Selected canine variants are assessed against the strength, relevance and clinical limitations of the available evidence.
Results are organised around clinical decisions and presented through a practical interface for veterinarians.
Genotype, medication and outcome data can support continuing evidence development and future species expansion.
Designed for clinical use
A single cheek swab is intended to create a pre-emptive genetic profile that can be available when relevant prescribing decisions arise.
Collaboration
Loom is seeking partners who can contribute to responsible validation, veterinary integration and commercial development as the platform moves towards clinical pilots.
Start a conversationLoom also supports selected genetics and reproductive-health initiatives in Australia and New Zealand.
Make an enquiry